Physician profile
Drew Heiple
NPI 1376665646
$236,463.52
in general payments reported to CMS, 2019-2025
27 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $6,226 · 2021: $9,142 · 2022: $36K · 2023: $58K · 2024: $53K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $165K · Travel and Lodging: $14K · Food and Beverage: $6,360 · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $164,543.31 |
| Travel and Lodging | $13,740.61 |
| Food and Beverage | $6,360.25 |
| Education | $388.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $161,861.29 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Novo Nordisk INC | $66,331.05 | 2023-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $2,881.58 | 2019-2023 | Krystexxa |
| Mozarc Medical US LLC | $1,585.36 | 2024 | Argyle |
| Travere Therapeutics, INC. | $633.68 | 2023-2025 | Filspari |
| Amgen INC. | $570.98 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $443.59 | 2021-2025 | |
| Vifor Pharma, INC. | $277.54 | 2019-2025 | Veltassa |
| Medtronic, INC. | $263.57 | 2021-2023 | Ellipsys Vascular Access System |
| Fresenius USA Marketing, INC. | $216.72 | 2021-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $213.42 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $198.16 | 2020-2025 | Acthar |
| Ardelyx, INC. | $171.09 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $115.18 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $114.47 | 2021-2025 | Jynarque |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $105.32 | 2021-2023 | Lupkynis |
| Bard Peripheral Vascular, INC. | $104.07 | 2020 | |
| Akebia Therapeutics INC | $77.11 | 2021-2025 | Vafseo |
| Glaxosmithkline, LLC. | $58.73 | 2021-2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.67 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $46.90 | 2025 | |
| Cormedix INC. | $38.37 | 2024 | Defencath |
| Takeda Pharmaceuticals U.S.A., INC. | $31.84 | 2021-2023 | Gattex |
| Boston Scientific Corporation | $29.88 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $15.12 | 2024 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $15.08 | 2020 | |
| Cook Medical LLC | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Heiple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.